The Twenty Minute VC (20VC): Venture Capital | Startup Funding | The Pitch
20VC: Why Raising A First Time Fund Is Like Raising A Seed Round, Why We Need New and Different Fund Models & Why Longevity Is The Most Rewarding Place To Invest with Laura Deming, Founding Partner @ The Longevity Fund
The Twenty Minute VC (20VC) interviews the world's greatest venture capitalists with prior guests including Sequoia's Doug Leone and Benchmark's Bill Gurley. Once per week, 20VC Host, Harry Stebbings is also joined by one of the great founders of our time with prior founder episodes from Spotify's Daniel Ek, Linkedin's Reid Hoffman, and Snowflake's Frank Slootman.
If you would like to see more of The Twenty Minute VC (20VC), head to www.20vc.com for more information on the podcast, show notes, resources and more.
Show Notes
Laura Deming is Founding Partner @ The Longevity Fund, the first VC firm dedicated to funding high-potential longevity companies. To date, Laura has raised $26m across 2 Longevity funds and has backed the likes of Unity Biotechnology, Precision Biosciences, Metacrine, Navitor, and Alexo Therapeutics. Prior to Longevity, Laura was accepted to MIT at the age of 14 to study physics and then dropped out to join the Thiel Fellowship and start The Longevity Fund. If that wasn't enough, Laura most recently founded Age1, a four-month startup accelerator program focused on founders creating longevity companies.
In Today's Episode You Will Learn:
1.) How Laura made her way from studying physics at MIT at just 14 to founding The Longevity Fund and dropping out to join The Thiel Fellowship?
2.) As a 16-year-old, looking to raise a fund to invest in longevity, how was the fundraise process for Laura? Why does Laura believe that raising your first fund is very much like raising a seed round for a company? What was the catalytic moment when the fundraise started to come together? What were the biggest challenges of the raise?
3.) Why does Laura believe that there is a shortage of young biotech founders today? What can be done to solve this and increase pipe? How does Laura find biotech founders compare to more traditional consumer and B2B founders she engages with? How does what they look for from their investor base differ?
4.) Laura has spoken before of "the importance of going against the herd"? How does Laura assess the current landscape for biotech investing? Is Laura concerned to see the entrance of much more traditional VCs into the space? How does Laura look to try and avoid groupthink? What is crucial to this?
5.) How does one need to think about portfolio construction when investing in an inherently riskier biotech space? Does Laura agree with the conventional wisdom around the lack of follow-on funding for biotech companies? How does Laura think about reserve allocation with Longevity today?
Items Mentioned In Today's Show:
Laura's Fave Book: The Mysterious Stranger by Mark Twain,
Laura's Most Recent Investment: System1
As always you can follow Harry, The Twenty Minute VC and Laura on Twitter here!
Likewise, you can follow Harry on Instagram here for mojito madness and all things 20VC.
Transcript not yet processed.
Sign in to unlock (1 credit)
Free to start
Full transcripts, AI insights,
Full transcripts, AI insights,
episode chat — free.
Sign up with Google in one click. 10 unlock credits included. No card needed.
Google sign-in · No credit card · Cancel anytime